Short Communication High-Dose Hydroxyurea, Mucocutaneous Toxicity

Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 6, pp 496-497

First online:

Acute mucocutaneous toxicity following high-dose hydroxyurea

  • Hans BrinckerAffiliated withDepartment of Hematology, Odense University Hospital
  • , Bjarne Egelund ChristensenAffiliated withDepartment of Hematology, Odense University Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Three patients with advanced acute myeloid leukemia were treated with oral high-dose hydroxyurea at a dose of 10 g daily for 8–10 days. Severe acute stomatitis developed in all three patients. In addition, two of the patients developed a peculiar acute cutaneous type of toxicity associated with soreness, violet erythema, and edema of the palms and foot soles followed by intense universal hyperpigmentation of the skin. Apparently, the pronounced acute mucocutaneous toxicity was caused by the sustained high daily dose of hydroxyurea, indicating that myelosuppression may not be the dose-limiting toxicity of this drug.